Stock Market News
BTG tumbles as 2019 guidance disappoints
Specialist healthcare company BTG issued final results that beat sales and earnings expectations, though financial guidance for the new trading year was slightly short of the market's current estimate.
Revenues in the year to 31 March improved 9% to £620.5m, or 10% at constant exchange rates as product sales rose 9% to £423.8m while licensing revenues grew 7% year-on-year to £196.7m.
Adjusted operating profit was ahead 18%, or 20% at constant currency, to £152.7m, although the company swung to an IFRS operating loss of £102.8m, from a profit of £57.5m in the 2017 financial year. Adjusted basic earnings per share surged 42% to 32.9p, beating the consensus forecast of 29.8p.
Free cash flow swelled 69% to £109.3m and net cash flow from operating activities rose 63% to £120.7m. Cash and cash equivalents at year-end stood at £210m, up from £155.5m at the end of the 2017 financial year.
"Over the past decade we have been transforming BTG from a royalties business into a product sales business with diverse, sustainable revenue streams," said CEO Louise Makin.
"We have built the capabilities and infrastructure that support ongoing growth, by investing our strong cash flows to develop leading positions in selected Interventional Medicine markets and to maintain a strong pharmaceuticals business."
Makin said the company was "well positioned" to continue generating around double-digit product sales growth through the anticipated royalty declines, and to deliver operating leverage over the medium term.
"By continuing to invest in product innovation, clinical data, geographic expansion and acquisitions, we are developing leading positions in attractive growth markets and creating significant long-term value for shareholders."
Makin issued guidance for the new financial year of 13-15% sales growth at constant exchange rates in the interventional oncology and vascular business, a flat to single digit CER decline in pharmaceuticals and a flat to single digit decline in adjusted SG&A and R&D costs.
Noting that consensus expectations for 2019 revenue had been for around £620m, analysts at Shore Capital said that assuming a circa 20% fall in licensing revenues and a minimal contribution from early stage Interventional Medicine assets, "we would estimate guidance suggests a FY2019 revenue range of £595m-£600m, which hence looks light vs. consensus forecasts".
Revenues in the year to 31 March improved 9% to £620.5m, or 10% at constant exchange rates as product sales rose 9% to £423.8m while licensing revenues grew 7% year-on-year to £196.7m.
Adjusted operating profit was ahead 18%, or 20% at constant currency, to £152.7m, although the company swung to an IFRS operating loss of £102.8m, from a profit of £57.5m in the 2017 financial year. Adjusted basic earnings per share surged 42% to 32.9p, beating the consensus forecast of 29.8p.
Free cash flow swelled 69% to £109.3m and net cash flow from operating activities rose 63% to £120.7m. Cash and cash equivalents at year-end stood at £210m, up from £155.5m at the end of the 2017 financial year.
"Over the past decade we have been transforming BTG from a royalties business into a product sales business with diverse, sustainable revenue streams," said CEO Louise Makin.
"We have built the capabilities and infrastructure that support ongoing growth, by investing our strong cash flows to develop leading positions in selected Interventional Medicine markets and to maintain a strong pharmaceuticals business."
Makin said the company was "well positioned" to continue generating around double-digit product sales growth through the anticipated royalty declines, and to deliver operating leverage over the medium term.
"By continuing to invest in product innovation, clinical data, geographic expansion and acquisitions, we are developing leading positions in attractive growth markets and creating significant long-term value for shareholders."
Makin issued guidance for the new financial year of 13-15% sales growth at constant exchange rates in the interventional oncology and vascular business, a flat to single digit CER decline in pharmaceuticals and a flat to single digit decline in adjusted SG&A and R&D costs.
Noting that consensus expectations for 2019 revenue had been for around £620m, analysts at Shore Capital said that assuming a circa 20% fall in licensing revenues and a minimal contribution from early stage Interventional Medicine assets, "we would estimate guidance suggests a FY2019 revenue range of £595m-£600m, which hence looks light vs. consensus forecasts".
Related share prices |
---|
BTG (BTG) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price